ES2652595T3 - Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas - Google Patents
Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas Download PDFInfo
- Publication number
- ES2652595T3 ES2652595T3 ES11700612.2T ES11700612T ES2652595T3 ES 2652595 T3 ES2652595 T3 ES 2652595T3 ES 11700612 T ES11700612 T ES 11700612T ES 2652595 T3 ES2652595 T3 ES 2652595T3
- Authority
- ES
- Spain
- Prior art keywords
- alpha
- olida
- dihydroxy
- beta
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000008589 Obesity Diseases 0.000 title abstract description 3
- 235000020824 obesity Nutrition 0.000 title abstract description 3
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229930009674 sesquiterpene lactone Natural products 0.000 title 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 5
- 125000000217 alkyl group Chemical group 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 239000001257 hydrogen Substances 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 239000012453 solvate Substances 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 description 5
- -1 2-hydroxymethylpropenoyl Chemical group 0.000 description 3
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 244000019459 Cynara cardunculus Species 0.000 description 2
- 235000019106 Cynara scolymus Nutrition 0.000 description 2
- KHSCYOFDKADJDJ-NQLMQOPMSA-N Cynaropicrin Chemical compound OCC(=C)C(=O)O[C@H]1CC(=C)[C@@H]2C[C@H](O)C(=C)[C@@H]2[C@H]2OC(=O)C(=C)[C@H]12 KHSCYOFDKADJDJ-NQLMQOPMSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- KHSCYOFDKADJDJ-UHFFFAOYSA-N Saupirin Chemical compound OCC(=C)C(=O)OC1CC(=C)C2CC(O)C(=C)C2C2OC(=O)C(=C)C12 KHSCYOFDKADJDJ-UHFFFAOYSA-N 0.000 description 2
- STQKFHDZSADKCG-UHFFFAOYSA-N cynaropicrin Natural products OC1CC2C(C3OC(=O)C(=C)C3C(CC2=C)OC(=O)C(=C)O)C1=C STQKFHDZSADKCG-UHFFFAOYSA-N 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- LWHRXFOPIDTJSG-NUJMLJBLSA-N Dentalactone Natural products O=C1[C@H](C)[C@@H]2[C@H](O)CC(=C)[C@H]3[C@H]([C@@H](C)[C@@H](O)C3)[C@H]2O1 LWHRXFOPIDTJSG-NUJMLJBLSA-N 0.000 description 1
- LWHRXFOPIDTJSG-XPIVLIJGSA-N Isolipidiol Natural products O=C1[C@@H](C)[C@@H]2[C@@H](O)CC(=C)[C@H]3[C@H]([C@H](C)[C@@H](O)C3)[C@@H]2O1 LWHRXFOPIDTJSG-XPIVLIJGSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto de fórmula (I), para uso en el tratamiento o la prevención de la obesidad en un animal de sangre caliente. **(Ver fórmula)** en la que, A1, A2 y A3 independientemente el uno del otro representan los dirradicales ** CH2, ** CH-O-R1, o ** C >= O, y B1, B2 y B3 independientemente el uno del otro representan los dirradicales ** C>=CH2, ** CH-CH2-R1, o ** C(OH)-CH2-O-R1; en la cual, R1 es hidrógeno, un grupo alquilo de cadena lineal o de cadena ramificada que tiene de 1 a 12 átomos de carbono, o un grupo -C(O)-(CH2)n-CRa >= CRaRb (donde n es cero o un número entero de 1 a 12 y Ra y Rb independientemente entre sí se seleccionan de un grupo Z, que consiste en hidrógeno y un grupo alquilo de cadena lineal o cadena ramificada que tiene de 1 a 6 átomos de carbono que no está sustituido o está sustituido con hidroxilo), y R1 * es R1 como se definió anteriormente o un grupo alcoxi de cadena lineal o cadena ramificada que tiene de 1 a 12 átomos de carbono, donde el compuesto de fórmula (I) se puede presentar en forma libre, en forma de una sal farmacéutica y/o nutracéuticamente aceptable, en forma de tautómeros y/o en forma de solvatos.
Description
especialmente la disminución de la grasa corporal) y, por lo tanto, ellos mismos son el principio activo importante para el (los) tratamiento(s) mencionado(s). A lo largo de la presente especificación, el tratamiento o regulación profiláctica y/o terapéutica del peso corporal y/o pérdida de grasa y/o tratamiento de la obesidad, especialmente la disminución del peso corporal, más especialmente la disminución de la grasa corporal, son realizaciones especialmente preferidas de acuerdo con la divulgación.
En cualquiera de los USO(s) mencionados, los compuestos de la fórmula I se pueden presentar y/o administrar en forma libre, en forma de una sal farmacéuticamente y/o nutracéuticamente aceptable, en forma de tautómeros, en forma de ésteres y/ o en forma de solvatos.
Además o alternativamente, las siguientes combinaciones y su USO o USO(s) se excluyen preferiblemente de la presente divulgación, aunque la técnica anterior no menciona explícitamente que Cynara scolymus existe el principio activo en los USO(s) de acuerdo con la presente descripción:
Lo extractos que se preparan a partir de Cynara scolymus con la adición de aminoácidos sulfatados o tío-derivados adecuados, especialmente cisteína.
Por "administrar" se entiende especialmente, en el presente documento, la administración de una dosis terapéutica o nutracéuticamente eficaz de un compuesto de la fórmula I, o una mezcla de compuestos de la fórmula I, en una célula, en cultivo celular o especialmente en un animal, especialmente un paciente humano. Por "dosis terapéutica o nutracéuticamente efectiva" se entiende preferiblemente, en el presente documento, una dosis que produce los efectos para los que se administra.
Las preparaciones farmacéuticas o nutracéuticas se pueden esterilizar y/o pueden contener materiales de soporte o adyuvantes tales como conservantes, estabilizadores, aglutinantes, disgregantes, agentes humectantes, potenciadores de la penetración de la membrana mucosa o de la piel, emulsionantes, sales para variar la presión osmótica y/o reguladores, u otros ingredientes, excipientes o materiales de soporte que se conocen en la técnica.
Descripción de las figuras
Figura 1: Representación gráfica de la ganancia de peso corporal en correlación con el grupo de control, los pesos corporales de los grupos de control se normalizaron a 1,00 (pérdida de peso en ratas mediante la administración de cinaropicrina).
Figura 2: Representación gráfica de la ganancia de grasa corporal (determinada por DEXA) en correlación con el grupo de control, la grasa corporal de los grupos de control se normalizó a 1,00 (reducción de grasa corporal en ratas mediante cinaropicrina).
Figura 3: Análisis por HPLC del extracto enriquecido de acuerdo con el ejemplo 4A; línea superior ELSD, línea inferior UV (210 nm).
Figura 4: Análisis por HPLC del producto final de acuerdo con el ejemplo 5 que se identifica como Cinaropicrina (IMD-009047); línea superior ELSD, tiempo determinado 9,372 min, línea inferior UV (210 nm), tiempo determinado 9,235 min.
Figura 5: Figura 3: Análisis por HPLC de un extracto de acuerdo con el ejemplo 4 B; UV (210 nm).
Realizaciones preferidas de la divulgación
En una realización preferida, la descripción se refiere a un USO de un compuesto de la fórmula I o una mezcla de dos o más de dichos compuestos, en la que
A1, A2 y A3 independientemente el uno del otro representan los dirradicales ** CH2, ** CH-O-R1, o ** C = O,
con R1 que denota hidrógeno, un grupo alquilo de cadena lineal o cadena ramificada que tiene 1 a 12 átomos de carbono o un grupo (-C (O) -(CH2)n-CRa = CRaRb) en el que de n es cero o un número entero de 1 a 12 y,
Ra y Rb independientemente entre sí se seleccionan de un grupo Z, que consiste en hidrógeno, un grupo alquilo de cadena lineal o cadena ramificada que tiene de 1 a 6 átomos de carbono que no está sustituido o está sustituido con hidroxi,
y
- Nombres
- CAS-RN
- Isolipidiol3,8-DihIdroxI-10(14)-guaien-12,6-olida; (1alfa,3beta,4alfa,5alfa,6alfa,8alfa,11alfa)Dentalactona3,8-Dihidroxi-10(14)-guaien-12,6-olida; (1alfa,3beta,4beta,5alfa,6alfa, 8beta,11beta)
-
imagen15 308662-30-9
- Isoamberboina3,8-Dihidroxi-10(14)-guaien-12,6-olida; (1alfa,3beta,4alfa,5alfa,6alfa,8alfa,11alfa);3-Cetona 8-Hidroxi-3-oxo-10(14)-guaien-12,6-olida
-
imagen16 30825-69-5 22339-28-2
- Nombres
- CAS-RN
- 3-Epi-11,13-dihidrodeacilcinaropicrina3,8-Dihidroxi-4(15),10(14)-guaiadien-12,6-olida; (1alfa,3alfa,5alfa,6alfa,8alfa, 11betaH)11,13-Dihidrodeacilcinaropicrina 3, 8-Dihidroxi-4(15),10(14)-guaiadien-12,6-olida;(1alfa,3beta,5alfa,6alfa,8alfa,11betaH)3,8-Dihidroxi-4(15),10(14)-guaiadien-12,6-olida8alfa-Hidroxi-11alfa,13-dihidrozaluzanina3,8-Dihidroxi-4(15),10(14)-guaiadien-12,6-olida(1alfa,3beta,5alfa,6alfa,8alfa,11alfaH),8-Dihidroxi-4(15),10(14)-guaiadien-12,6-olida;forma-(1alfa,3beta,5alfa,6alfa,8beta,11alfaH) 8beta-Hidroxi-11beta,13-dihidrozaluzanina C8-Dihidroxi-4(15),10(14)-guaiadien-12,6-olida; (1alfa,3beta,5alfa,6alfa,8beta, 11betaH)
-
imagen17 99305-01-8 66761-12-4 35932-54-8 848753-47-0
- Nombres
- CAS-RN
- 8-Hidroxi-3-oxo-4(15),10(14)-guaiadien-12,6-olida3,8-Dihidroxi-4(15),10(14)-guaiadien-12,6-olida; (1alfa,3beta,5alfa,6alfa,8alfa,11betaH); 3-Cetona; 8-Hidroxi-3-oxo-4(15),10(14)-guaiadien12,6-olida
-
imagen18 38142-62-0
- 3,8-Dihidroxi-10(14),11(13)-guaiadien-12,6-olida3,8-Dihidroxi-10(14)-guaien-12,6-olida; forma-(1alfa,3beta,4alfa,5alfa,6alfa,8beta,11alfa); 11,13-Dideshidro
-
imagen19 843283-65-0
- Nombres
- CAS-RN
- 8-Epigrosheimina3,8-Dihidroxi-10(14)-guaien-12,6-olida; (1alfa,4alfa,5alfa,6alfa,8beta);11,13-Dideshidro3-cetonaGrossheimina8-Hidroxi-3-oxo-10(14),11(13)-guaiadien-12,6-olida
-
imagen20 -22489-66-3
- 3,8-Dihidroxi-4(15),10(14),11(13)guaiatrien-12,6-olida; forma-(1xi,3xi,5xi,6xi,8xi) Integrifolina
- 3,8-Dihidroxi-4(15),10(14),11(13)guaiatrien-12,6-olida; (1alfa,3beta,5alfa,6alfa,8beta) 8-Hidroxizaluzanina C
- 89647-87-0
- 3,8-Dihidroxi 4(15),10(14),11(13)-guaiatrien-12,6-olida; (1alfa,3beta,5alfa,6alfa,8alfa)
- 31565-50-1
- 8beta-Hidroxideshidroxizaluzanina C
- 83991-71-3
- 3,8-Dihidroxi-4(15),10(14),11(13)
- guaiatrien-12,6-olida;
- (1alfa,3beta,5alfa,6alfa,8beta); 3-Cetona
- 8-Hidroxi-3-oxo
- 67667-77-0
- 4(15),10(14),11(13)-guaiatrien-12,6-olida
- Cinaratriol 3,11,13-Trihidroxi4(15),10(14)-guaiadien12,6-olida; (1alfa,3beta,5alfa,6alfa,11alfa); 4beta,15-Dihidro
- 70894-20-1
- Nombres
- CAS-RN
- Sibtorpina3,11,13-Trihidroxi-4(15),10(14)-guaiadien-12,6-olida; (1alfa,3alfa,5alfa,6alfa,11alfa)Solstitialina3,11,13-Trihidroxi-4(15),10(14)-guaiadien-12,6-olida; (1alfa,3beta,5alfa,6alfa,11alfa)
-
imagen21 94410-23-8 22738-70-1
- 8-Deoxi-11,13-dihidroxigrosheimina11,13-Dihidroxi-3-oxo-10(14)-guaien-12,6-olida; (1alfa,4alfa,5alfa,6alfa,11xi)3,11,13-Trihidroxi-4(15),10(14)-guaiadien-12,6-olida;forma-(1alfa,3beta,5alfa,6alfa,11alfa); 4,15-Dihidro, 3-cetona11,13-Dihidroxi-3-oxo-10(14)-guaien-12,6-olida; forma-(1alfa,4alfa,5alfa,6alfa,11alfa)
-
imagen22 835722-99-7
- Muricatina3,8-Dihidroxi-10(14)-guaien-12,6-olida; (1alfa,3beta,4alfa,5alfa,6alfa,8alfa, 11alfa); 11,13-Dideshidro, 8-O-(2-hidroximetilpropenoil)
-
imagen23 52597-25-8
- Nombres
- CAS-RN
- Cinaropicrina3,8-Dihidroxi-4(15),10(14),11(13)-guaiatrien-12,6-olida;(1alfa,3beta,5alfa,6alfa,8alfa); 8-O-(2-Hidroximetil-2-propenoil)Saupirina 3,8-Dihidroxi-4(15),10(14),11(13)-guaiatrien-12,6-olida; (1xi,3xi,5xi,6xi,8xi); 8-O-(2-Hidroximetilpropenoil)
-
imagen24 35730-78-0 35932-39-9
Claims (1)
-
imagen1 imagen2 imagen3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10000282 | 2010-01-14 | ||
| EP10000282A EP2345646A1 (en) | 2010-01-14 | 2010-01-14 | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
| PCT/EP2011/000110 WO2011085979A1 (en) | 2010-01-14 | 2011-01-13 | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2652595T3 true ES2652595T3 (es) | 2018-02-05 |
Family
ID=42727406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11700612.2T Active ES2652595T3 (es) | 2010-01-14 | 2011-01-13 | Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20130023586A1 (es) |
| EP (3) | EP2345646A1 (es) |
| DK (1) | DK2523946T3 (es) |
| ES (1) | ES2652595T3 (es) |
| HU (1) | HUE037455T2 (es) |
| NO (1) | NO2523946T3 (es) |
| PL (1) | PL2523946T3 (es) |
| PT (1) | PT2523946T (es) |
| WO (1) | WO2011085979A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2661266B1 (en) | 2011-01-07 | 2020-09-16 | Anji Pharma (US) LLC | Chemosensory receptor ligand-based therapies |
| US9795792B2 (en) | 2011-02-25 | 2017-10-24 | Medtronic, Inc. | Emergency mode switching for non-pacing modes |
| ITMI20111670A1 (it) * | 2011-09-16 | 2013-03-17 | Indena Spa | Estratti di cynara scolimus per il trattamento di dislipidemie |
| EP2800562A2 (en) | 2012-01-06 | 2014-11-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| US20150157675A1 (en) * | 2012-04-02 | 2015-06-11 | Sung Kyun Biotech Co., Ltd. | Composition comprising eupatorium spp. extract as active ingredient for preventing and treating obesity and metabolic bone disease |
| US10047034B2 (en) | 2012-05-16 | 2018-08-14 | Prairie Berry Europe Gmbh | Polyhydroxylated pentacyclic triterpene acids as HMG-COA reductase inhibitors |
| HK1210825A1 (en) | 2012-07-11 | 2016-05-06 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| KR101378431B1 (ko) * | 2012-11-05 | 2014-03-27 | 초당약품공업 주식회사 | 세스퀴터핀 락톤계 위장 질환 치료용 의약 조성물 |
| KR101378433B1 (ko) | 2012-11-05 | 2014-03-27 | 초당약품공업 주식회사 | 세스퀴터핀 락톤계 위장 질환 치료용 의약 조성물 |
| CN105101956B (zh) | 2013-01-05 | 2018-12-07 | 埃尔舍利克斯治疗公司 | 包含双胍的延迟释放组合物 |
| CN104016952B (zh) * | 2013-02-28 | 2016-05-18 | 东北林业大学 | 一种倍半萜活性成分及其制备方法与应用 |
| FR3011180B1 (fr) * | 2013-10-01 | 2017-01-06 | Laboratoires De Biologie Vegetale Yves Rocher | Utilisation d'un extrait d'artemisia montana dans une composition cosmetique amincissante |
| KR101926075B1 (ko) * | 2017-01-05 | 2018-12-06 | 동신대학교산학협력단 | 명월초에서 분리한 화합물 등을 이용한 항당뇨 조성물 |
| CN107118188A (zh) * | 2017-05-09 | 2017-09-01 | 中国科学院新疆理化技术研究所 | 天山雪莲种子中的倍半萜内酯类化合物及其制备方法 |
| CN108003174A (zh) * | 2017-12-18 | 2018-05-08 | 南开大学 | 一种倍半萜衍生物的晶型及其制备方法与用途 |
| KR102406792B1 (ko) * | 2019-12-20 | 2022-06-10 | 주식회사 봄프렌즈 | 다이어트 기능성 개과 동물용 사료 조성물 |
| CN118978558B (zh) * | 2024-10-22 | 2025-01-24 | 江西中医药大学 | 杏香兔耳风中的一种倍半萜类化合物及其制备方法与应用 |
| CN119564670B (zh) * | 2024-11-19 | 2025-11-18 | 澳门大学 | 愈创木脂内酯在制备治疗脆性x染色体综合征的药物中的应用 |
| CN121731292A (zh) * | 2026-02-27 | 2026-03-27 | 浙江大学医学院附属第二医院 | 菜蓟苦素在治疗急性呼吸窘迫综合征和抑制nlrp3炎症小体中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH617326A5 (es) | 1975-12-04 | 1980-05-30 | Siegfried Ag | |
| EP1175901B1 (en) * | 1999-04-15 | 2006-05-31 | Kaneka Corporation | Peroxisome activator-responsive receptor agonists |
| US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
| JP2005503381A (ja) * | 2001-08-15 | 2005-02-03 | 岐阜県 | 脂肪細胞分化阻害作用を有するセスキテルペノイド誘導体 |
| KR100469612B1 (ko) * | 2003-02-05 | 2005-02-02 | 주식회사 싸이제닉 | 흰씀바귀로부터 추출된 세스퀴테르펜 락톤계 화합물 및이를 함유하는 심혈관 질환 및 암 치료용 조성물 |
| KR100552109B1 (ko) * | 2003-02-05 | 2006-02-14 | 학교법인 경희대학교 | 흰씀바귀로부터 추출된 세스퀴테르펜 락톤 화합물을 함유하는 심혈관 질환 예방 및 치료용 조성물 |
| KR100572621B1 (ko) | 2003-03-19 | 2006-04-24 | 한국 한의학 연구원 | 비만 및 성인병 치료용 조성물 |
| WO2004096252A1 (en) | 2003-04-25 | 2004-11-11 | Primavera Biosciences, Inc. | Compositions and methods for weight loss |
| JP2006206532A (ja) | 2005-01-31 | 2006-08-10 | Ichimaru Pharcos Co Ltd | ＮＦ−κＢ活性化抑制剤 |
| ITMI20051347A1 (it) * | 2005-07-14 | 2007-01-15 | Indena Spa | Estratti di cynara scolimus loro uso e formulazioni che li contengono |
| ATE431155T1 (de) * | 2007-03-07 | 2009-05-15 | Indena Spa | Formulierungen mit extrakten aus cynara scolymus und phaseolus vulgaris zur behandlung von adipositas |
| JP2008231031A (ja) * | 2007-03-20 | 2008-10-02 | Arkray Inc | デヒドロエピアンドロステロン産生促進剤およびその用途 |
| WO2009005115A1 (ja) * | 2007-07-03 | 2009-01-08 | Nisshin Pharma Inc. | 脂肪細胞の小型化促進用組成物 |
| KR100905419B1 (ko) * | 2008-09-11 | 2009-07-02 | 연세대학교 산학협력단 | 세스퀴테르펜 유도체의 용도 |
-
2010
- 2010-01-14 EP EP10000282A patent/EP2345646A1/en not_active Withdrawn
-
2011
- 2011-01-13 ES ES11700612.2T patent/ES2652595T3/es active Active
- 2011-01-13 EP EP11700612.2A patent/EP2523946B1/en not_active Not-in-force
- 2011-01-13 NO NO11700612A patent/NO2523946T3/no unknown
- 2011-01-13 US US13/522,110 patent/US20130023586A1/en not_active Abandoned
- 2011-01-13 EP EP17185407.8A patent/EP3260449A1/en not_active Withdrawn
- 2011-01-13 PT PT117006122T patent/PT2523946T/pt unknown
- 2011-01-13 DK DK11700612.2T patent/DK2523946T3/en active
- 2011-01-13 HU HUE11700612A patent/HUE037455T2/hu unknown
- 2011-01-13 PL PL11700612T patent/PL2523946T3/pl unknown
- 2011-01-13 WO PCT/EP2011/000110 patent/WO2011085979A1/en not_active Ceased
-
2019
- 2019-03-21 US US16/360,164 patent/US20200055835A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200055835A1 (en) | 2020-02-20 |
| HUE037455T2 (hu) | 2018-08-28 |
| EP3260449A1 (en) | 2017-12-27 |
| WO2011085979A4 (en) | 2011-09-29 |
| PT2523946T (pt) | 2017-12-13 |
| NO2523946T3 (es) | 2018-02-17 |
| EP2523946B1 (en) | 2017-09-20 |
| WO2011085979A1 (en) | 2011-07-21 |
| PL2523946T3 (pl) | 2018-02-28 |
| DK2523946T3 (en) | 2018-01-08 |
| EP2523946A1 (en) | 2012-11-21 |
| EP2345646A1 (en) | 2011-07-20 |
| US20130023586A1 (en) | 2013-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2652595T3 (es) | Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas | |
| ES2218638T3 (es) | Uso de inhibidores de la histona-descarboxilasa para tratar la fibrosis. | |
| CA3127211C (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| AR068816A1 (es) | Composiciones de brimonidina mejorada para el tratamiento del eritema | |
| US9782426B2 (en) | Anti-viral therapeutic composition | |
| KR20070112762A (ko) | 프리 라디칼 질환 예방 치료용 조성물 | |
| ES2661106T3 (es) | Formulaciones de crema estabilizadas que comprenden aceite de sándalo | |
| JP2012502020A (ja) | ポリヒドロキシルテート（ｐｏｌｙｈｙｄｒｏｘｙｌｔａｔｅ）脂肪アルコールおよび誘導体を含む化粧品組成物およびその使用 | |
| Hu et al. | Pyruvate-enriched oral rehydration solution improved intestinal absorption of water and sodium during enteral resuscitation in burns | |
| JP2018513130A (ja) | Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用 | |
| Cai et al. | Up-regulation of Thioredoxin 1 by aerobic exercise training attenuates endoplasmic reticulum stress and cardiomyocyte apoptosis following myocardial infarction | |
| US9987329B2 (en) | Methods for treating peripheral nerve damage | |
| KR20120014788A (ko) | 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물 | |
| ES3042094T3 (en) | Vaginal delivery systems containing selective estrogen receptor modulator (serm) and uses thereof | |
| TWI232750B (en) | Bile secretion promoting composition | |
| KR20220098144A (ko) | 암을 치료하는 데에 사용하기 위한 알파-메틸-dl-티로신의 알킬에스테르 | |
| KR20060061367A (ko) | 디파이브로타이드를 단독으로 또는 다른 항암제들과조합하여 포함하는 항암제제 | |
| WO2014041393A1 (es) | Combinación de compuestos derivados del ácido gálico para el tratamiento del cáncer | |
| JP2022501372A (ja) | 審美的皮膚状態を治療する為の鉄キレート化合物 | |
| US11685760B2 (en) | Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same | |
| JP2002302447A (ja) | 局所投与用癌治療剤 | |
| CN103893200A (zh) | 虫草素用于制备预防和治疗动脉粥样硬化的药物 | |
| ES2969209T3 (es) | Composiciones y métodos para proteger órganos de lesiones por isquemia/reperfusión asociadas con el trasplante | |
| JP2007527851A (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 | |
| KR102435793B1 (ko) | 섬유증의 억제 또는 치료 방법 |